Clinical trials: House Dust Mite Allergy

Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal

Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

• Completed
• Age: 12 years and older
• Phase 3
• Pill or oral medicine
• Injection or infusion
• Results posted

The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults.

Trial name

NCT01700192

Testing

MK-8237 tablets, Rescue Medication: Self-Injectable Epinephrine, Rescue Medication: Loratadine tablets

Volunteers

1,482 people

Sponsor

ALK-Abelló A/S